South Korea Raises Interest Rates to 2.75% as Inflation and Weak Won Drive Tightening 
China Q2 2026 GDP Misses Forecast as Weak Domestic Demand Offsets Export Strength 
Volkswagen Launches €28,000 ID. Cross EV as Europe’s Electric Vehicle Demand Accelerates 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Asian Currencies Stay Rangebound as Middle East Tensions, Weak China GDP Weigh on Sentiment 
Asian Stocks Slide as Chip Selloff Deepens Ahead of TSMC Earnings 
Volvo Cars Q2 Profit Falls as Automaker Bets on EX60 EV to Drive Recovery 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Gold Price Holds Near Record High as Cooling U.S. Inflation Offsets Fed Caution 
Moonshot Launches Kimi K3, China's Largest Open-Source AI Model 
Oil Prices Climb as Trump Escalates Iran Pressure, Strait of Hormuz Risks Grow 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
Brent Oil Jumps 16% for Best Week Since April as US-Iran Conflict Fuels Supply Fears 
Dollar Slides as Softer US Inflation Dims Fed Rate Hike Expectations 
IEA Warns China Rare Earth Export Curbs Could Threaten $6.5 Trillion in Global Production 
Trump Criticizes ABC, NBC and CNN for Limiting Coverage of Election Speech 
SK bioscience said on Wednesday, Nov. 23, that it has stopped the production of its COVID-19 vaccine called the SKY Covione. The biotechnology wing of the SK Group said that it is a temporary decision that was made because of the declining demand for the product.
SK bioscience mentioned that one of the reasons for the falling demand for its COVID-19 vaccine is the decreasing number of infections. Moreover, the company said the approval of requirements set by drug agencies and global health organizations have also contributed to its move to suspend the manufacturing of SKY Covione.
The spin-off of SK Chemicals, which specializes in the development and production of vaccines, named the World Health Organization (WHO) and the European Medicines Agency (EMA) as some of the groups that have set stricter rules over vaccine approvals.
In any case, despite the suspension of production, the spokesperson of SK bioscience shared that the liquid base materials being used as the main ingredient of the SKY Covione vaccines are still in production. He explained that only the final product is suspended.
"The production of finalized vaccines has been suspended, with no additional orders from the government," an official at the company told The Korea Herald. "However, the vaccine bulk is still being produced. With the bulk (finished products), we are currently waiting for the next orders of SKYCovione from the government."
The official said that the key ingredients are still being manufactured as they are needed to meet the demands once international health agencies grant their approvals. The tight regulations also restricted the exports of vaccines to developing countries such as Africa so it will take more time before the vaccines reach them.
Meanwhile, it was reported that all the unused doses of SK bioscience’s SKYCovione vaccines are likely to be discarded. This is the first ever COVID-19 vaccine that the country has produced and approved.
"The original monovalent vaccine is for people getting their first or second shots, but most Korean people have completed their first vaccination," the Korea Disease Control and Prevention Agency (KDCA) commissioner, Peck Kyong Ran, said in a statement. "Doses that we are planning to buy under an existing deal will be highly likely discarded, as well as those that we've already purchased."
Photo by: Daniel Schludi /Unsplash
